Experimental Dengue Vaccine Protects Against 3 Of 4 Viral Strains, Study Results Show

“The world’s first vaccine against dengue fever, being developed by French drugmaker Sanofi SA, protected against three of the virus’s four strains in a keenly awaited clinical trial in Thailand,” the company announced on Wednesday, Reuters reports (Hirschler/Regan, 7/25). “The vaccine actually generated antibody responses against all four strains of the virus, but for some reason, one strain was still able to infect children who received the vaccine, the company said, and scientists are now trying to figure out why,” the Los Angeles Times’ “Science Now” blog reports, adding, “Meanwhile, a much larger trial involving 31,000 adults and children is now under way in 10 countries in Asia and Latin America” (Maugh, 7/26). Reuters notes, “Other drug companies are also working on dengue vaccines but Sanofi’s product is several years ahead” (7/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.